3 July
2019
Arix Bioscience plc
Issue of Ordinary Shares, Total Voting
Rights and PDMR Shareholding Notifications
Issue of Ordinary Shares
Arix Bioscience plc (the "Company") announces that it has
allotted 84,249 new Ordinary Shares to certain Non-Executive
Directors, in accordance with the Company’s Remuneration Policy and
the compensation agreed at their appointments, as follows:
| Name of
Non-Executive Director |
Number of shares
allotted |
| Art Pappas |
47,619 |
| Mark Breuer |
36,630 |
Application has been made for 84,249 new Ordinary Shares to be
admitted to the standard segment of the Official List and to
trading on the Main Market of the London Stock Exchange. The new
Ordinary Shares will rank pari passu with the existing ordinary
shares and it is expected that admission of these new Ordinary
Shares will take place at 8.00 a.m.
on 4 July 2019.
Total Voting Rights
Following the issue of 84,249 shares the Company will have a
total of 135,551,850 ordinary shares of £0.00001 each in issue and
a total number of voting rights in the Company of 135,551,850. The
above figure of 135,551,850 may be used by shareholders as the
denominator for the calculation by which they may determine if they
are required to notify their interest in, or change to their
interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
PDMR Notification
The Trustee of the Arix Bioscience plc Employee Benefit Trust
has notified the Company that it has delivered 241,545 shares to
Jonathan Peacock, Chairman,
following the vesting of conditional share awards issued under the
Arix Bioscience plc Executive Incentive Plan.
PDMR Dealing Notifications
| PDMR
DEALING NOTIFICATION |
|
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them |
| 1 |
Details
of the person discharging managerial responsibilities / person
closely associated |
| a) |
Name |
Art
Pappas |
| 2 |
Reason
for the notification |
| a) |
Position / status |
Non-Executive Director |
| b) |
Initial
notification /
Amendment |
Initial
Notification |
| 3 |
Details
of issuer |
| a) |
Name |
Arix
Bioscience plc |
| b) |
LEI |
213800OVT3AHQCXNIX43 |
| 4 |
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
| a) |
Description of the
financial instrument, type of instrument |
Ordinary
Shares of Arix Bioscience plc |
| Identification
code |
GB00BD045071 |
| b) |
Nature of the
transaction |
Award of Ordinary Shares |
| c) |
Price(s)
and volume(s) |
Price(s) |
Volume(s) |
| £1.3650 |
47,619 |
| d) |
Aggregated
information |
Aggregated price |
Aggregated volume |
| N/A (single
transaction) |
N/A (single
transaction) |
| e) |
Date of the
transaction |
02 July
2019 |
| f) |
Place of the
transaction |
London
Stock Exchange (XLON) |
| PDMR
DEALING NOTIFICATION |
|
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them |
| 1 |
Details
of the person discharging managerial responsibilities / person
closely associated |
| a) |
Name |
Mark
Breuer |
| 2 |
Reason
for the notification |
| a) |
Position / status |
Non-Executive Director |
| b) |
Initial
notification /
Amendment |
Initial
Notification |
| 3 |
Details
of issuer |
| a) |
Name |
Arix
Bioscience plc |
| b) |
LEI |
213800OVT3AHQCXNIX43 |
| 4 |
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
| a) |
Description of the
financial instrument, type of instrument |
Ordinary
Shares of Arix Bioscience plc |
| Identification
code |
GB00BD045071 |
| b) |
Nature of the
transaction |
Award of Ordinary Shares |
| c) |
Price(s)
and volume(s) |
Price(s) |
Volume(s) |
| £1.3650 |
36,630 |
| d) |
Aggregated
information |
Aggregated price |
Aggregated volume |
| N/A (single
transaction) |
N/A (single
transaction) |
| e) |
Date of the
transaction |
02 July
2019 |
| f) |
Place of the
transaction |
London
Stock Exchange (XLON) |
| PDMR
DEALING NOTIFICATION |
|
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them |
| 1 |
Details
of the person discharging managerial responsibilities / person
closely associated |
| a) |
Name |
Jonathan
Peacock |
| 2 |
Reason
for the notification |
| a) |
Position / status |
Chairman |
| b) |
Initial
notification /
Amendment |
Initial
Notification |
| 3 |
Details
of issuer |
| a) |
Name |
Arix
Bioscience plc |
| b) |
LEI |
213800OVT3AHQCXNIX43 |
| 4 |
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
| a) |
Description of the
financial instrument, type of instrument |
Ordinary
Shares of Arix Bioscience plc |
| Identification
code |
GB00BD045071 |
| b) |
Nature of the
transaction |
Vest of
nil-cost Conditional share award under the Arix Bioscience plc
Executive Incentive Plan |
| c) |
Price(s)
and volume(s) |
Price(s) |
Volume(s) |
| Nil |
241,545 |
| d) |
Aggregated
information |
Aggregated price |
Aggregated volume |
| N/A (single
transaction) |
N/A (single
transaction) |
| e) |
Date of the
transaction |
02 July
2019 |
| f) |
Place of the
transaction |
London
Stock Exchange (XLON) |
For further information:
Robert
Lyne
Chief Operating
Officer
+44 (0)207 290 1050
- Ends -